For International Audiences: The REDUCER I trial demonstrated #
ShockwaveReducer#'s real-world impact on patients, with the following benefits at one year:
➡️ 66% decrease in total number of emergency department visits in the year after implantation
➡️ 71% ≥1 CCS improvement
➡️ 26% ≥2 CCS improvement
Learn more:
Watch the study's lead investigator, Dr Stefan Verheye, discuss the 12-month results:
Verheye S. et al. European Heart Journal. (2024) Vol 45 (Suppl 1)
Safety info link in Bio. CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.